These trials highlight the potential of SGLT2 inhibitors to improve cardiovascular outcomes in patients with diabetes, which may extend to cancer populations with a high prevalence of diabetes and cardiovascular risk factors. This evidence concerns the gene SLC5A2 and cancer.